The availability of a human bivalent antigen-binding antibody directed against CD99 (dAbd C7) [94,95] that is able to efficiently deliver a cell death message in Ewing sarcoma cells while sparing normal cells [53], opens new therapeutic perspectives for all tumors in which the expression of CD99 is maintained at high levels and supports tumor progression. Here, CD99 is linked to neoplasm.